David Slatter

Father to three gorgeous boys, husband to the amazing Michelle, CEO at S&C Slatter, White Horse Contractors and Mavid Investments Ltd.

[David Slatter @DSSlatter]

These two photos make me very proud 😊 #sportshubspecialists

[TVR5 @TVR5AVCT]

#AVCT renders CLN irrelevant with transfer from Heights to an institutional investor.

An expectation AVA6103 will effectively treat human cancers confirmed.

Ensuring Gen 1, 2 & 3 license deal negotiations are unencumbered by noise during this critical period.

Different board.

[Mark Mitchell @emily1katie]

#AVCT - Essentially saying we expect 6103 to work! 💥

[RAH @RAH00084]

Question: Why has the most scientifically literate non-exec member of #AVCT’s board taken part in a placing, 9+ weeks into AVA6103, having opted to sit out every historic placing (incl the March 2026 subscription)?

Answer: the sustained released of Exatecan in human.

Dynamite.

[MBC Advocate @MBCadvocate]

A Phase 1, Open Label, Dose-Escalation and Expansion Study to Evaluate Safety, Pharmacokinetics and Initial Therapeutic Activity of AVA6103, a Novel FAP-activated Exatecan Administered Intravenously in Patients w/Locally Advanced or Metastatic Selected Solid Tumors. #AVCT #ASCO26

[TVR5 @TVR5AVCT]

#AVCT

“We’re hoping we see something more in the
middle range of our dose levels”

[Avacta @avacta]

In this video presentation, Avacta CEO Christina Coughlin reviews the new faridoxorubicin program data. https://t.co/nN63I5Cxzf #AVCT

[Charlton Athletic FC @CAFCofficial]

Pitch renovation work has begun at The Valley as preparations for the 2026/27 season get under way 🌱

#cafc

[Avacta @avacta]

Avacta today released updated Phase 1a/1b and pharmacokinetics, safety, toxicity and preliminary efficacy data with faridoxorubicin at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. https://t.co/yQ7kjJpSbP #AVCT

[RAH @RAH00084]

#AVCT shareholders will feel the full impact of this appointment not today but when the board is deciding which offer to recommend to shareholders.

Board now ultra lean. Coughlin, Hughes + x3 NEDs. No bloat. Little waste.

Unrecognisable from 12 months ago.

[Richard Hughes @hughesy0707]

In my personal view 2026 will be a defining point for #AVCT and ultimately for long term cancer patients.

Thanks to all shareholders and stakeholders for their support.

[Richard Hughes @hughesy0707]

Delighted to be appointed as chairman of #AVCT

My core priority is to ensure the value of preCISION is exploited to its fullest, for the benefit of all shareholders.

I am more than confident we have the team and the intellectual property to enable this.

[TVR5 @TVR5AVCT]

Congratulations to Richard Hughes on his appointment as Chair of #AVCT.

@TVR5AVCT looks forward to a transformative H2 under his chairmanship.

We wish Shaun Chilton all the best for the future.

[Avacta @avacta]

Avacta today announces that Richard Hughes, one of Avacta’s non-executive Directors, will become non-executive Chairman of Avacta following the Annual General Meeting (AGM) on June 22, 2026. https://t.co/25k4YieSX7 #AVCT

[TVR5 @TVR5AVCT]

@coughlin582 of @avacta therapeutics is the obvious choice @bradloncar.

#AVCT

[TVR5 @TVR5AVCT]

Following yesterday’s interims, #AVCT is clearly in the depths of multiple commercial negotiations across all iterations of their pipeline. Funded into Q127 with multiple upcoming data catalysts due. We await news on the expedited route we know the company has sought for AVA6000.

[Avacta @avacta]

We’re pleased to share the recordings from our Science Day. The presentations explore comparative analyses of pre|CISION® payload delivery with AVA6103 vs approved ADCs, alongside updated in vivo studies of the AVA6207 dual payload delivery system. https://t.co/oV0amuV74Q #AVCT

[Mike Gardner @mikegardner_wb]

Piers Morgan to Wes Streeting:

“It’s the worst kind of politics of envy”.

Watch as Morgan takes down Labour’s flagship policy of destroying independent schools with a destructive tax grab.

A perfect critique in barely 1 minute.

@piersmorgan #bbcqt

[TVR5 @TVR5AVCT]

#AVCT management will have their first insight into AVA6103’s efficacy today.

[TVR5 @TVR5AVCT]

“#AVCT is not just challenging Enhertu.
It is rewriting the metric the entire ADC industry will be diligenced on. Tumor selectivity is the new battleground”

Exactly.

[stonks @JStonker]

https://t.co/0K4oyY0d6o

#AVCT